Know Cancer

forgot password

A Phase I Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors

Phase 1
18 Years
Open (Enrolling)
Advanced Solid Tumors

Thank you

Trial Information

A Phase I Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors

Inclusion Criteria:

- Incurable advanced solid tumors that are no longer responding to conventional therapy
or for which no effective therapy exists

- Age 18 years or older

- ECOG 0-2

- Life expectancy ≥ 3 months

- Evaluable disease

- Adequate bone marrow function

- Adequate renal function

- Adequate liver function

- At least 3 weeks from prior systemic treatments including investigational anti-cancer
therapy, radiation therapy; and have recovered from prior toxicities

- Able to swallow capsules

- At least 3 weeks from major surgery

- Agree to practice effective contraception

- Ability to understand and willingness to sign the informed consent form

Exclusion Criteria:

- Previously untreated CNS metastases or progressive CNS metastases

- Currently receiving radiotherapy, biological therapy, or any other investigational

- Uncontrolled intercurrent illness including

- Pregnant or lactating women

- Known to be HIV-positive

- A history of active hepatitis B and/or hepatitis C infection

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

maximum tolerated dose

Outcome Time Frame:

1-3 months

Safety Issue:


Principal Investigator

Geoffrey Shapiro, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Dana-Farber Cancer Institute


United States: Food and Drug Administration

Study ID:




Start Date:

February 2009

Completion Date:

September 2012

Related Keywords:

  • Advanced Solid Tumors
  • Neoplasms



Dana Farber Cancer Institute Boston, Massachusetts  02115